This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ORADUR-ADHD
ORADUR-Methylphenidate utilizes the active ingredient methylphenidate which is a norepinephrine and dopamine reuptake inhibitor. It allows for the increase of the dopamine and norepinpehrine neurotransmitter in the brain by partially blocking the dopamine transporter (DAT) in the presynaptic neuron thus stimulating the neuron to release more of the neurotransmitters into the synapse.
It is being developed based on DURECT’s ORADUR Technology for the treatment of ADHD. This drug candidate is intended to provide once-a-day dosing with added tamper resistant characteristics to address common methods of abuse and misuse of these types of drugs.
DURECT and Orient Pharma
In August 2009, DURECT entered into a development and license agreement with Orient Pharma Co., Ltd., under which DURECT granted to Orient Pharma development and commercialization rights in certain defined Asian and South Pacific countries to ORADUR-ADHD. DURECT retains rights to North America, Europe, Japan and all other countries not specifically licensed to Orient Pharma.
Under the agreement with Orient Pharma, the parties will collaborate to perform a clinical development program through a Phase II study intended to produce a data package suitable for further development of the drug candidate by DURECT as well as Orient Pharma in their respective territories. DURECT will be responsible for formulation and study design of the Phase I and Phase II clinical program which Orient Pharma has agreed to fund and execute. Orient Pharma would be responsible for all remaining development and commercialization activities for ORADUR-ADHD in the licensed...See full deal structure in Biomedtracker
Partners: Orient Europharma Co., Ltd.
Pink Sheet “Complete Response” Letters
Additional information available to subscribers only: